Type 2 Diabetes T2D Pipeline Analysis [Report Updated: 09062015] Prices from USD $3600

12:56 EDT 18 Aug 2017 | BioPortfolio Report Blog

Type 2 Diabetes T2D Pipeline Analysis gives comprehensive insight on the various drugs being developed for the treatment of T2D. The report covers all the drugs being developed in various phases Discovery, Preclinical, Clinical Marketing. The pipeline focuses on novel pharmacologic drugs regenerative medicines covering small molecules, monoclonal antibodies, stem cell therapies, Gene therapies, Recombinant proteins and RNAbased therapeutics, but excludes symptom relief drugs, generic combinations. The report also covers some of the hot targets in research for T2D treatments and disease progression biomarkers.
This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Type 2 Diabetes T2D Drug market. The report also provide strategic insights on medicines that are likely to have an impact on T2D treatment space and potentially alter standards of care in T2D in the foreseeable future.
Current therapies are focused on the treatment of hyperglycemia than on pancreatic Beta cell dysfunction and they lose efficacy over time as both endogenous insulin secretion and insulin sensitivity decrease. There is a need for type 2 diabetes therapies that act in concert with available agents to provide adequate glycemic control without causing hypoglycemia and weight gain, which are associated with increase in cardiovascular risk. Hence, it provides a tremendous opportunity for upcoming therapies specific to T2D such as MAbs, stem cellbased, gene therapies and RNAbased therapies. These modalities may provide betacell protection, regeneration, mass increase with additional benefits of weight loss, triglyceride lowering and kidney protection.

Original Article: Type 2 Diabetes T2D Pipeline Analysis [Report Updated: 09062015] Prices from USD $3600


More From BioPortfolio on "Type 2 Diabetes T2D Pipeline Analysis [Report Updated: 09062015] Prices from USD $3600"

Quick Search


Relevant Topics

Biological Therapy
Biological therapy involves the use of living organisms, substances derived from living organisms, or laboratory-produced versions of such substances to treat disease. Some biological therapies for cancer use vaccines or bacteria to stimulate the body&rs...

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...